医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Over-the-Counter Represents 45 Percent of the Global Consumer Health Industry in 2016

2016年09月13日 PM07:00
このエントリーをはてなブックマークに追加


 

CHICAGO

Global market research company Euromonitor International released today new consumer health industry data. According to the new research, global sales of consumer health products will reach USD $217 billion globally in 2016 – a 3 percent growth from 2015.

Over-the-counter (OTC) medicine represents 45 percent of the consumer health industry at USD $98.5 billion in 2016. The main driver of this growth stems from prescription (Rx) drugs switching to OTC, especially in allergy care.

“An important push to switch drugs from prescription to OTC or non-prescription drugs continues to bring new market expansion opportunities for firms,” Monica Feldman, head of consumer health industry research at Euromonitor International, says. “This is especially true in the therapeutic areas of respiratory and digestive health and esomeprazole.”

The U.S. continues to dominate the consumer health space representing 31 percent of the overall industry at USD $67 billion in 2016. Paired with China, Japan, Germany and Italy, these five countries comprise 61 percent of global sales within consumer health, confirming that the industry is mainly driven by developments in a few geographies. This finding also signals an opportunity for market expansion in other countries with only 1 to 2 percent global share in 2016, including South Korea, France, India and Mexico amongst others.

“This year, the new proposition for consumer health is founded on a formidable shift toward lifestyle and wellness programmes supported by a holistic approach to self-care,” Feldman continues. “These factors will create a unique window of opportunity based on the personalization of consumer health.”

To learn more, visit: http://www.euromonitor.com/consumer-health

About Euromonitor International

Euromonitor International is the world’s leading provider for global business intelligence and strategic market analysis. We have more than 40 years of experience publishing international market reports, business reference books and online databases on consumer markets.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160913005029/en/

CONTACT

Euromonitor International
Marissa Bosler
Communications
Executive
Tel: +1 (312) 477-8908
Email: marissa.bosler@euromonitor.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
  • Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy
  • No Dogs Left Behind Meat Market Survivors Coming Home
  • Takeda’s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease
  • Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据